Zanamivir: Clinical Trials

20 trials of Zanamivir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 completed, 3 terminated, 2 recruiting. 6 Phase 2, 6 Phase 3, 5 Phase 1, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 26Completed 3, Recruiting 2, Terminated 1
Phase 36Completed 4, Terminated 2
Phase 15Completed 5
Phase 41Completed 1

Follow Zanamivir: new trials by email Literature Review of Zanamivir trials Research Report on Zanamivir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
Zanamivir, Placebo - Dengue Fever
Phase 2RecruitingGeorge Washington University742024-03-152026-07-29
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
Oseltamivir, Favipiravir, Zanamivir - Influenza, Influenza, Human
Phase 2RecruitingUniversity of Oxford30002023-02-222026-04-14
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
Zanamivir - Influenza, Human, Arthralgia
Phase 2CompletedGlaxoSmithKline82022-11-212026-07-28
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Zanamivir - Diabetes Mellitus, Type 2
Phase 2CompletedUniversity of Missouri-Columbia142021-07-142025-04-25
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Zanamivir - Influenza, Human
Phase 1CompletedGlaxoSmithKline242015-04-282017-05-09
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
Intravenous (IV) zanamivir - Influenza, Human
Phase 3CompletedGlaxoSmithKline212012-01-012018-02-22
Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Zanamivir, Placebo - Influenza A Virus Infection, Influenza B Virus Infection
Phase 3CompletedJiangsu Simcere Pharmaceutical Co., Ltd.2982011-10-012013-01-16
Safety of Inhaled Zanamivir in Pregnancy
Treatment with zanamivir - Influenza, Human
CompletedGlaxoSmithKline12011-07-012014-04-21
A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo - Influenza, Human
Phase 1CompletedGlaxoSmithKline402011-05-192017-07-21
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
Zanamivir, Placebo to match zanamivir, Oseltamivir - Influenza, Human
Phase 3CompletedGlaxoSmithKline6262011-01-152018-10-15
Relenza® Sentinel Site Monitoring Program in Japan
zanamivir - Influenza, Human
CompletedGlaxoSmithKline15752009-11-012017-07-06
Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
Zanamivir - Influenza A Virus, H1N1 Subtype
Phase 1CompletedGlaxoSmithKline182009-10-122017-06-14
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
Oseltamivir, Zanamivir, Placebo of Oseltamivir - Upper Respiratory Tract Infection, Influenza
Phase 3TerminatedChinese University of Hong Kong42009-10-012011-04-11
Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
active oseltamivir, placebo capsule, zanamivir for inhalation - Influenza
Phase 4CompletedUniversity of Oxford3902009-09-012010-09-22
Prophylactic Efficacy of Relenza Against Influenza A and B
Receiving a prescription of Relenza for prophylaxis, No prophylaxis with Relenza - Pulmonary Disease, Chronic Obstructive, Bronchospasm
CompletedGlaxoSmithKline1717052009-07-012017-05-30
Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults
Zanamivir, Oseltamivir - Influenza, Virus Diseases
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)172009-07-012010-03-19
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD - Influenza
Phase 1 / Phase 2CompletedFred Hutchinson Cancer Center72009-03-012013-08-15
Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection
oseltamivir + zanamivir, oseltamivir+ amantadine, oseltamivir - Influenza A Infection
Phase 2TerminatedHospices Civils de Lyon602009-01-012010-09-30
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
oseltamivir + zanamivir, oseltamivir + zanamivir's placebo, oseltamivir's placebo + zanamivir - Gastric Influenza
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris5412008-12-012012-03-19
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
Fluviral, Zanamivir - Influenza
Phase 3CompletedMount Sinai Hospital, Canada642008-11-012014-11-21

Conditions studied

Influenza, Human (14)  ·  Arthralgia (1)  ·  Asthma (1)  ·  Bronchial Spasm (1)  ·  Bronchitis (1)  ·  Dengue (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Orthomyxoviridae Infections (1)  ·  Pneumonia (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Respiration Disorders (1)  ·  Respiratory Tract Diseases (1)  ·  Respiratory Tract Infections (1)  ·  Sinusitis (1)  ·  Virus Diseases (1)

Sponsors

GlaxoSmithKline (9)  ·  University of Oxford (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Chinese University of Hong Kong (1)  ·  Fred Hutchinson Cancer Center (1)  ·  George Washington University (1)  ·  Hospices Civils de Lyon (1)  ·  Jiangsu Simcere Pharmaceutical Co., Ltd. (1)  ·  Mount Sinai Hospital, Canada (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  University of Missouri-Columbia (1)

Countries

United States (5)  ·  China (4)  ·  Thailand (4)  ·  France (3)  ·  Brazil (2)  ·  Canada (2)  ·  Colombia (2)  ·  Hong Kong (2)  ·  Poland (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Germany (1)

Top investigators

Aileen Chang, MD (1)  ·  Allison McGeer, MD (1)  ·  Luis Martinez-Lemus, PhD (1)  ·  Michael Boeckh, MD (1)  ·  Qingyu Xiu, MD (1)  ·  Sasithon Pukrittayakamee, MD (1)

Results publications

PMID 21072246, PMID 22264308, PMID 23264438, PMID 25470818, PMID 28094141, PMID 28698321, PMID 30170561, PMID 36202198, PMID 37801046, PMID 42520824

NIH funding

2008 (1), N01AO50042 (1)